Remission Rates, Survival, and Prognostic Factors in Ninety Patients with Advanced Myelodysplastic Syndromes Treated with Intensive Chemotherapy

Aul, C.; Runde, Volker; Germing, Ulrich; Burk, M.; Heyll, A.; Hildebrandt, Barbara; Willers, R.

doi:10.1007/978-3-642-60377-8_143

Cited by 6 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was, however, a trend for PR patients to have more abnormal karyotypes and unfavourable karyotypes than patients who achieved CR, and more RAEB-T at diagnosis than patients who had failure. The incidence of PR after IC in MDS was 16% in our experience, and ranged from 9% to 35% in the few studies where this figure was available (Martiat et al, 1989;Michels et al, 1989;Hirst & Mufti, 1994;Aul et al, 1995b;Gore et al, 1995). However, PR criteria were not always given in detail in those reports, and those available were often less stringent than in our study.…”

Section: Discussionmentioning

confidence: 54%

“…Many other published studies had too short a follow-up to evaluate the incidence of long-term survivors. Some studies have reported 4-year survivals in 0-25% of patients (Gore et al, 1995;Aul et al, 1995b), but those figures are generally actuarial survivals, few of the patients having a follow-up > 4 years. Thus, the cure rate after IC in MDS is very low, and lower than that observed in de novo AML (Gajewski et al, 1989;De Witte et al, 1990;Fenaux et al, 1991).…”

Section: Discussionmentioning

confidence: 99%

“…Many reports in the last few years have shown that IC gave lower CR rates and shorter CR duration than in de novo AML (Martiat et al, 1988;Michels et al, 1985;Hoyle et al, 1990;Gajewski et al, 1989;De Witte et al, 1990;Fenaux et al, 1991;De Witte et al, 1995b;Bernstein et al, 1993;Ruutu et al, 1994;Aul et al, 1994Aul et al, , 1995bHiddeman et al, 1995;Gore et al, 1995;Wattel et al, 1996b;Gardin et al, 1997). However, follow-up of these studies was generally short, and the number of long-term survivors could usually not be determined.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders

Wattel¹,

Botton²,

Laı̈³

et al. 1997

Br J Haematol

View full text Add to dashboard Cite

Summary. The percentage of long-term survivors after intensive chemotherapy and the outcome of MDS patients who achieve partial remission (PR) with intensive chemotherapy (IC) are not known.Between 1981 and 1996 we treated 99 patients with de novo MDS who had high-risk MDS or progression to AML, with IC. 41 (41%) achieved CR, 16 (16%) achieved partial remission (PR), 26 (26%) had failure, and 16 (16%) died in aplasia. Eight of the patients who achieved CR were autografted, three were allografted and the remaining cases received moderate consolidation chemotherapy.After IC, the 16 PR patients fulfilled the criteria for RA in 15 cases and CMML in one case. Median PR duration was 17 months, and three PR were > 3 years (39, 50þ, 82þ months). Median actuarial survival of patients who achieved PR and CR was 18 months and 20 months from the onset of IC, respectively (difference not significant).Of the 71 patients treated before 1993, with sufficient follow-up, 10 (14%) had survived > 4 years (long-term survivors). Four of them were alive in first CR after 49þ to 110þ months and probably cured, two were alive in PR after 50þ and 82þ months and four had died after 49-78 months. Long-term survivors were characterized by a significantly higher incidence of RAEB-T at diagnosis, and with normal or favourable cytogenetic findings. In patients with RAEB-T at diagnosis included before 1993, 8/23 (35%) cases who had no unfavourable karyotype had survived > 4 years. Our findings suggest that MDS patients who achieve PR with IC, and not only those who achieve CR, can benefit from this type of treatment. The percentage of long-term survivors remains low, however, and is almost restricted to patients with RAEB-T at diagnosis and no unfavourable karyotype.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders

Wattel¹,

Botton²,

Laı̈³

et al. 1997

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Patients with good risk karyotypes (normal karyotype, isolated deletions of chromosome 20 (del(20q)), chromosome 5 (del(5q)), or loss of the Y chromosome as sole abnormality) have a more favorable prognosis. Those high-risk MDS patients who display a normal karyotype may occasionally benefit from intensive "AML-like" chemotherapy and achieve long-term remissions [23,24]. Conversely, MDS patients with poor risk cytogenetics (complex aberrant karyotypes and/or alterations involving chromosome 7) have a very unfavorable prognosis [6,25,26].…”

Section: Chromosomal Abnormalitiesmentioning

confidence: 99%

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

et al. 2010

View full text Add to dashboard Cite

To cite this version:Katharina Götze, Uwe Platzbecker, Aristoteles Giagounidis, Detlef Haase, Michael Lübbert, et al.. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Annals of Hematology, Springer Verlag, 2010, 89 (9) Abstract Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML). For many years, the main treatment option for MDS was best supportive care which alleviates symptoms, but has no effect on the natural course of the disease. Recently, demethylating agents have become available as a promising new treatment for patients with MDS. In two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, improvement of peripheral blood values, an improved quality of life, and a definite survival advantage compared to conventional care regimens for patients with International Prognostic Scoring System score of intermediate-2 or high-risk MDS. This review aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, assuring safe administration and best efficacy of treatment.

show abstract

“…Kombinationspartner für die Induktionschemotherapie sind Anthracycline, Anthrachinone, Standard-und HochdosisAra-C, Epipodophyllotoxine und Topoisomerase-I-Hemmer (Topotecan). In neueren Studien mit Einschluss von mindestens 30 Patienten (Tabelle 5) betragen die Vollremissionsraten 45-79% [20][21][22][23][24][25][26]. Als prädiktive Parameter für Therapieansprechen konnten primäres MDS, morphologische Diagnose einer RAEB/T, Nachweis von Auer-Stäb-chen, weibliches Geschlecht, niedrige LDH-Serumkonzentration und Fehlen chromosomaler Aberrationen definiert werden.…”

Section: Intensive Polychemotherapieunclassified

Myelodysplastische Syndrome

Aul

Giagounidis²,

Germing³

et al. 2002

Medizinische Klinik

View full text Add to dashboard Cite

show abstract

Remission Rates, Survival, and Prognostic Factors in Ninety Patients with Advanced Myelodysplastic Syndromes Treated with Intensive Chemotherapy

Cited by 6 publications

References 7 publications

Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders

Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

Myelodysplastische Syndrome

Contact Info

Product

Resources

About